By Adrian Galbreth
The treatment of retinal conditions has both increased and changed in the past ten years, the latest study has suggested.
According to a report in the October issue of the Archives of Ophthalmology, the last decade has seen "substantial changes" in the treatment options available, particularly in the care of neovascular age-related macular degeneration (AMD).
The report shows that new therapies such as intravitreal therapy, which involves injecting drugs directly into the eye, are rising in popularity among medical professionals.
Lead author Dr Pradeep Ramulu, from the Wilmer Eye Institute at Johns Hopkins University, Baltimore, commented: "We observe that intravitreal injections of pharmacologic agents have gained widespread acceptance for the treatment of neovascular AMD and that vitrectomy is being increasingly applied to a wide range of retinal conditions."
It comes after research published by TMCNet showed that the rate of nearsightedness diagnoses has soared to 41.6 per cent in the US, leading to Americans spending an annual average of $31.7 billion (£19.8 billion) on vision products and services, including glasses and contact lenses.
by Alexa Kaczka